Kessler Topaz Meltzer & Check, LLP: Investigation on Behalf of Sarepta Therapeutics, Inc. Shareholders

Kessler Topaz Meltzer & Check, LLP ("Kessler Topaz") announces an investigation of potential securities fraud claims on behalf of purchasers of Sarepta Therapeutics, Inc. ("Sarepta") (NASDAQ: SRPT) securities between August 7, 2019 and January 7, 2021.

Sarepta is a commercial-stage biopharmaceutical company, which focuses on the discovery and development of RNA-targeted therapeutics, gene therapy, and other genetic therapeutic modalities approaches for the treatment of rare diseases.

Kessler Topaz's investigation concerns whether Sarepta’s public statements concerning its gene therapy research may have been false and misleading. On January 7, 2021, after market hours, Sarepta announced its gene therapy as a one-time treatment for the rare disorder Duchenne muscular dystrophy failed to show benefits compared with a placebo. Sarepta’s shares dropped almost 49.7%, or $83.95, from closing at $168.95 on January 7, 2021 to open at $85.00 on January 8, 2021. 

If you are a Serepta investor and would like more information about this investigation, please contact Kessler Topaz Meltzer & Check, LLP: James Maro, Esq. (484-270-1453) or Adrienne Bell, Esq. (484-270-1435); toll-free at (844) 887-9500; or via e-mail at [email protected]. You may also click on the link "Submit Your Information" above and fill out the form as promptly as possible.

CONTACT:
 Kessler Topaz Meltzer & Check, LLP
 James Maro, Esq. or Adrienne Bell, Esq.
 280 King of Prussia Road
 Radnor, PA 19087 
 1-844-887-9500 (toll free) or 1-610-667-7706 
 Or by e-mail at [email protected]